Silverlake Wealth Management LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,449 shares of the company’s stock after purchasing an additional 302 shares during the period. Johnson & Johnson comprises about 2.0% of Silverlake Wealth Management LLC’s portfolio, making the stock its 5th largest holding. Silverlake Wealth Management LLC’s holdings in Johnson & Johnson were worth $3,868,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of the business. Naviter Wealth LLC lifted its position in shares of Johnson & Johnson by 43.8% in the first quarter. Naviter Wealth LLC now owns 20,281 shares of the company’s stock valued at $3,208,000 after acquiring an additional 6,174 shares in the last quarter. Quattro Financial Advisors LLC lifted its holdings in Johnson & Johnson by 27,610.8% in the 1st quarter. Quattro Financial Advisors LLC now owns 43,506 shares of the company’s stock valued at $6,882,000 after purchasing an additional 43,349 shares in the last quarter. MV Capital Management Inc. boosted its stake in Johnson & Johnson by 5.3% during the 1st quarter. MV Capital Management Inc. now owns 18,942 shares of the company’s stock worth $2,996,000 after purchasing an additional 947 shares during the last quarter. Woodmont Investment Counsel LLC raised its position in shares of Johnson & Johnson by 2.9% in the first quarter. Woodmont Investment Counsel LLC now owns 81,823 shares of the company’s stock valued at $12,944,000 after buying an additional 2,318 shares during the last quarter. Finally, Exchange Capital Management Inc. lifted its stake in shares of Johnson & Johnson by 32.2% in the first quarter. Exchange Capital Management Inc. now owns 16,052 shares of the company’s stock worth $2,539,000 after buying an additional 3,912 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.
Johnson & Johnson Price Performance
Shares of JNJ opened at $145.62 on Thursday. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a market cap of $350.46 billion, a P/E ratio of 9.08, a PEG ratio of 2.43 and a beta of 0.52. The firm’s 50 day moving average price is $148.02 and its 200 day moving average price is $153.91.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date was Monday, May 20th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. Johnson & Johnson’s payout ratio is currently 30.92%.
Analyst Ratings Changes
JNJ has been the subject of a number of recent research reports. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America dropped their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. The Goldman Sachs Group started coverage on Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target on the stock. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $174.07.
View Our Latest Analysis on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- What is a Dividend King?
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Investing In Automotive Stocks
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- What does consumer price index measure?
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.